Jung Myung Lee1, Hancheol Lee2, Ajit H Janardhan3, Junbeom Park4, Boyoung Joung2, Hui-Nam Pak2, Moon-Hyoung Lee2, Sung Soon Kim5, Hye Jin Hwang6. 1. Department of Medicine, Graduate School, Kyung Hee University, Seoul, South Korea; Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, South Korea. 2. Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, South Korea. 3. Division of Cardiac Electrophysiology, Health First Medical Group, Cocoa Beach, Florida. 4. Division of Cardiology, Ewha Womans University, Seoul, South Korea. 5. Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, South Korea; Division of Cardiology, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, South Korea. 6. Division of Cardiology, Department of Internal Medicine, Yonsei University Health System, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: hhwang@bidmc.harvard.edu.
Abstract
BACKGROUND: Tissue refractoriness to conduction is a crucial electrophysiological factor in determining susceptibility to fibrillation. The relationship between atrial refractoriness and future onset of atrial fibrillation (AF) has not been well studied. OBJECTIVES: We investigated whether atrial effective refractory period (AERP) was associated with AF occurrence in a relatively healthy population. METHODS: A total of 1308 patients with no overt structural heart diseases and no evidence of congestive heart failure who underwent electrophysiology studies for paroxysmal supraventricular tachycardia from January 1986 to January 2011 were included in the study (626 male, mean age 44 ± 16 years). RESULTS: AERP increased with increasing age. Over a mean follow-up of 12 years, 51 of 1308 subjects (3.9%) developed AF. In univariate analysis, baseline AERP ≥280 ms (hazard ratio [HR] 2.54, 95% confidence interval [CI] 1.27-5.07, P = .008) was strongly associated with new-onset AF. In multivariate Cox regression analysis, age (adjusted HR 1.40 per 10 years, 95% CI 1.15-1.70, P = .001) and AERP ≥280 ms (adjusted HR 2.08, 95% CI 1.03-4.21, P = .041) were associated with new-onset AF. Kaplan-Meier AF-free survival curves demonstrated that subjects with an AERP of ≥280 ms had significantly lower AF-free survival compared those with AERP of <280 ms. CONCLUSIONS: AERP increases with age and AERP of ≥280 ms was predictive of patients at significantly increased future risk of developing AF.
BACKGROUND: Tissue refractoriness to conduction is a crucial electrophysiological factor in determining susceptibility to fibrillation. The relationship between atrial refractoriness and future onset of atrial fibrillation (AF) has not been well studied. OBJECTIVES: We investigated whether atrial effective refractory period (AERP) was associated with AF occurrence in a relatively healthy population. METHODS: A total of 1308 patients with no overt structural heart diseases and no evidence of congestive heart failure who underwent electrophysiology studies for paroxysmal supraventricular tachycardia from January 1986 to January 2011 were included in the study (626 male, mean age 44 ± 16 years). RESULTS: AERP increased with increasing age. Over a mean follow-up of 12 years, 51 of 1308 subjects (3.9%) developed AF. In univariate analysis, baseline AERP ≥280 ms (hazard ratio [HR] 2.54, 95% confidence interval [CI] 1.27-5.07, P = .008) was strongly associated with new-onset AF. In multivariate Cox regression analysis, age (adjusted HR 1.40 per 10 years, 95% CI 1.15-1.70, P = .001) and AERP ≥280 ms (adjusted HR 2.08, 95% CI 1.03-4.21, P = .041) were associated with new-onset AF. Kaplan-Meier AF-free survival curves demonstrated that subjects with an AERP of ≥280 ms had significantly lower AF-free survival compared those with AERP of <280 ms. CONCLUSIONS: AERP increases with age and AERP of ≥280 ms was predictive of patients at significantly increased future risk of developing AF.
Authors: Kaylin T Nguyen; Rachel A Gladstone; Jonathan W Dukes; Babak Nazer; Eric Vittinghoff; Nitish Badhwar; Vasanth Vedantham; Edward P Gerstenfeld; Byron K Lee; Randall J Lee; Zian H Tseng; Jeffrey E Olgin; Melvin M Scheinman; Gregory M Marcus Journal: Pacing Clin Electrophysiol Date: 2016-11-10 Impact factor: 1.976
Authors: Ann-Kathrin Rahm; Teresa Wieder; Dominik Gramlich; Mara Elena Müller; Maximilian N Wunsch; Fadwa A El Tahry; Tanja Heimberger; Steffi Sandke; Tanja Weis; Patrick Most; Hugo A Katus; Dierk Thomas; Patrick Lugenbiel Journal: Physiol Rep Date: 2021-06
Authors: Catherine E Lipovsky; Jesus Jimenez; Qiusha Guo; Gang Li; Tiankai Yin; Stephanie C Hicks; Somya Bhatnagar; Kentaro Takahashi; David M Zhang; Brittany D Brumback; Uri Goldsztejn; Rangarajan D Nadadur; Carlos Perez-Cervantez; Ivan P Moskowitz; Shaopeng Liu; Bo Zhang; Stacey L Rentschler Journal: JCI Insight Date: 2020-09-17
Authors: Antoinette F van Ouwerkerk; Fernanda M Bosada; Karel van Duijvenboden; Arjan C Houweling; Koen T Scholman; Vincent Wakker; Cornelis P Allaart; Jae-Sun Uhm; Inge B Mathijssen; Ton Baartscheer; Alex V Postma; Phil Barnett; Arie O Verkerk; Bastiaan J Boukens; Vincent M Christoffels Journal: Circulation Date: 2022-02-03 Impact factor: 29.690